Trial Profile
An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count <100 Cells/mm3.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 11 Mar 2010 New trial record